The IP6K1 Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population of the HT29 colorectal adenocarcinoma cell line with a targeted disruption of the IP6K1 gene. This pool provides a loss-of-function model for studying inositol hexakisphosphate kinase 1 (IP6K1) in an epithelial tumor background relevant to colorectal cancer. As a polyclonal product, it avoids artifacts of single-cell cloning while enabling robust investigation of IP6K1-dependent processes.
The parental HT29 cell line originates from a 44-year-old female colorectal adenocarcinoma and exhibits epithelial morphology with moderate differentiation. These adherent cells express intestinal markers and are widely employed as a model for colorectal tumor biology. The HT29 genetic background is microsatellite stable, with mutant p53 and wild-type APC, representing a common context in colorectal tumorigenesis. This well-characterized line supports comprehensive studies of cancer cell signaling, metabolism, and drug responses.
IP6K1 is the principal inositol hexakisphosphate kinase that converts inositol hexakisphosphate (IP6) to 5-diphosphoinositol pentakisphosphate (IP7), a key inositol pyrophosphate. IP7 generated by IP6K1 functions as an intracellular signal that modulates the PI3K/Akt pathway, insulin signaling, and DNA repair. IP6K1 is activated downstream of insulin receptor and growth factor stimulation through PI3K, and it directly interacts with and phosphorylates Akt, PDK1, and HSP90. Through these interactions, IP6K1 regulates the activation state of Akt, PDK1, GSK-3??, p53, and PTEN, thereby controlling cell proliferation, survival, and metabolic adaptation.
Disruption of IP6K1 in HT29 cells eliminates IP7 production, removing a negative regulatory input on Akt. Consequently, this knockout model is predicted to enhance Akt signaling, which may alter proliferation, apoptosis resistance, and migration in a colorectal adenocarcinoma context. The presence of mutant p53 allows investigation of the interplay between inositol pyrophosphate metabolism and p53-mediated processes such as apoptosis and genomic stability. Thus, these cells offer a valuable tool to dissect the contribution of IP6K1 to colorectal cancer phenotypes.
These polyclonal knockout cells support a breadth of experimental paradigms. Confirmation of IP6K1 deletion by Western blotting and reduction of IP7 by mass spectrometry provide primary validation. Downstream signaling effects can be assessed by phospho-specific flow cytometry for Akt and its substrates. Functional readouts include MTT/CCK-8 proliferation assays, Annexin V/PI apoptosis detection, transwell migration and invasion studies, and glucose uptake measurements. Transcriptomic profiling via RNA-seq and targeted interaction analysis by co-immunoprecipitation of Akt-IP6K1 complexes further expand utility. This model is a valuable resource for dissecting inositol pyrophosphate biology in colorectal cancer, suitable for target validation, pathway analysis, and drug discovery applications. For further details, please contact Ascent Research.
